GPC Biotech, Inc. Release: Orphan Drug Designation Granted By European Commission For Anticancer Monoclonal Antibody 1D09C3 For Chronic Lymphocytic Leukemia

MARTINSRIED/MUNICH, GERMANY -- (MARKET WIRE) -- 01/27/2006 -- U.S. Research and Development Facilities in Waltham/Boston, Mass. and Princeton, N.J. -- GPC Biotech AG (Frankfurt: GPC) (TecDAX index) (NASDAQ: GPCB) today announced that the European Commission has granted orphan drug designation for the anticancer monoclonal antibody 1D09C3 for the treatment of chronic lymphocytic leukemia (CLL). 1D09C3 is currently in a Phase 1 clinical trial that is evaluating the antibody in patients with relapsed or refractory B-cell lymphomas, such as Hodgkin’s and non-Hodgkin’s lymphomas including CLL, who have failed prior standard therapy.

MORE ON THIS TOPIC